ANGPTL3 and ovarian carcinoma: Given the availability of a monoclonal antibody against ANGPTL3 already used in patients with familial hypercholesterolemia, these results warrant further investigation of whether ANGPTL3 inhibition has therapeutic potential in ovarian cancers.